| Manufacturer: | Grand Pharma |
| Distributor: | AGlobal Care |
| Contents: | Aminophylline |
| Indications: | Management of reversible airway obstruction eg asthma, COPD, acute severe & chronic bronchospasm. Relieve neonatal apnea. |
| Dosage: | Management of acute severe bronchospasm Adult who have not been taking aminophylline, theophylline or other xanthines Loading dose 5mg/kg ideal body wt or 250-500 mg aminophylline IV over 20-30 min by slow inj or infusion, followed by a maintenance infusion dose of 500 mcg/kg/hr.Childn who have not been taking aminophylline, theophylline or other xanthines Loading dose of 5 mg/kg by slow inj or infusion over 20-30 min. Maintenance dose range: Childn 10-16 yr 500 mcg/kg/hr; 6 mth-10 yr 1 mg/kg/hr. |
| Special Precautions: | Patients w/ peptic ulceration, porphyria, hyperthyroidism, cardiac arrhythmia or other CV disease or epilepsy; heart failure, hepatic dysfunction, acute febrile illness. Neonates. Elderly. |
| Side Effects / Adverse Reactions: | Nausea, vomiting, abdominal pain, diarrhea, other GI disturbances, insomnia, headache, anxiety, irritability, restlessness, tremor, palpitations. Hypokalemia; sinus tachycardia, supraventricular & ventricular premature contractions; convulsions; hypersensitivity reactions; hyperuricemia; necrotizing enterocolitis. |
| Drug Interactions: | Reduce clearance w/ allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-α, macrolides, quinolones, OCs, thiabendazole, viloxazine. Increased clearance w/ phenytoin, other antiepileptics, ritonavir, rifampicin, sulfinpyrazone. Potentiate hypokalemia w/ β2agonists, corticosteroids & diuretics. Antagonize the effect of adenosine & neuromuscular blockers. Enhanced elimination of lithium. Halothane, ketamine; β-blockers. |
| Pregnancy Category (US FDA): | Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
| Therapeutic Category: | Antiasthmatic & COPD Preparations |
| ATC Classification: | R03DA05 – aminophylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway diseases. |
| Regulatory Classification: | Rx |
